Trial Profile

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zavegepant (Primary)
Indications Migraine
Focus Adverse reactions; Pharmacokinetics
Sponsors Biohaven Pharmaceutical Holding Company

Most Recent Events

31 Mar 2022 According to a Biohaven Pharmaceutical media release, the results from this trial will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting.
01 Apr 2019 Status changed from recruiting to completed, according to a Biohaven Pharmaceutical Holding Company media release.
04 Feb 2019 Results presented in the Biohaven Pharmaceutical Holding Company media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com